UniQure NV (QURE) - Financial and Strategic SWOT Analysis Review

UniQure NV (QURE) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH389133FSA
  • |
  • Pages: 53
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

UniQure NV (QURE)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UniQure NV (UniQure) develops and markets gene therapy products. The company develops adeno-associated virus based gene therapies using its gene technology platform. UniQure offers clinical and preclinical programs for lipoprotein lipase deficiency, hemophilia A and B, Huntington's disease, congestive heart failure and other research targets. The company develops a gene platform to bring new disease modifying therapies to patients with genetic diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions. UniQure is headquartered in Amsterdam, the Netherlands.

UniQure NV Key Recent Developments

Sep 28,2018: uniQure to Participate in Multiple Upcoming Industry Conferences

Aug 23,2018: uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

Aug 08,2018: uniQure announces second quarter 2018 financial results and highlights company progress

Jun 13,2018: uniQure Announces New Appointments to its Board of Directors

May 18,2018: uniQure presents preclinical data demonstrating advances in the distribution of gene therapy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

UniQure NV-Key Facts 6

UniQure NV-Key Employees 7

UniQure NV-Key Employee Biographies 8

UniQure NV-Major Products and Services 10

UniQure NV-History 11

UniQure NV-Company Statement 13

UniQure NV-Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2-Company Analysis 16

Company Overview 16

UniQure NV-Business Description 17

R&D Overview 17

UniQure NV-Corporate Strategy 18

UniQure NV-SWOT Analysis 19

SWOT Analysis-Overview 19

UniQure NV-Strengths 19

UniQure NV-Weaknesses 20

UniQure NV-Opportunities 21

UniQure NV-Threats 22

UniQure NV-Key Competitors 23

Section 3-Company Financial Ratios 24

Financial Ratios-Capital Market Ratios 24

Financial Ratios-Annual Ratios 25

Performance Chart 27

Financial Performance 27

Financial Ratios-Interim Ratios 28

Financial Ratios-Ratio Charts 29

Section 4-Company's Lifesciences Financial Deals and Alliances 30

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30

UniQure NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31

UniQure NV, Recent Deals Summary 32

Section 5-Company's Recent Developments 33

Aug 23, 2018: uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B 33

Aug 23, 2018: uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B 35

Aug 08, 2018: uniQure announces second quarter 2018 financial results and highlights company progress 37

Jun 13, 2018: uniQure Announces New Appointments to its Board of Directors 40

May 18, 2018: uniQure presents preclinical data demonstrating advances in the distribution of gene therapy 41

Apr 27, 2018: uniQure Announces to Present at Multiple Conferences in May 42

Mar 14, 2018: uniQure Announces 2017 Financial Results and Recent Company Progress 43

Feb 27, 2018: uniQure to Participate in Multiple Conferences in March 45

Jan 08, 2018: uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value 46

Dec 11, 2017: uniQure Added to NASDAQ Biotechnology Index 48

Section 6-Appendix 49

Methodology 49

Ratio Definitions 49

About GlobalData 53

Contact Us 53

Disclaimer 53

List of Figures

UniQure NV, Performance Chart (2013-2017) 27

UniQure NV, Ratio Charts 29

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30

UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 31

List of Tables

UniQure NV, Key Facts 6

UniQure NV, Key Employees 7

UniQure NV, Key Employee Biographies 8

UniQure NV, Major Products and Services 10

UniQure NV, History 11

UniQure NV, Subsidiaries 15

UniQure NV, Key Competitors 23

UniQure NV, Ratios based on current share price 24

UniQure NV, Annual Ratios 25

UniQure NV, Annual Ratios (Cont...1) 26

UniQure NV, Interim Ratios 28

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30

UniQure NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31

UniQure NV, Recent Deals Summary 32

Currency Codes 49

Capital Market Ratios 49

Equity Ratios 50

Profitability Ratios 50

Cost Ratios 51

Liquidity Ratios 51

Leverage Ratios 52

Efficiency Ratios 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Freeline Therapeutics Ltd

Expression Therapeutics LLC

bluebird bio Inc

BioMarin Pharmaceutical Inc

Bayer Corporation

AveXis Inc

Audentes Therapeutics Inc

Applied Genetic Technologies Corp

Adverum Biotechnologies Inc

UniQure NV, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8578
Site License
USD 250 INR 17155
Corporate User License
USD 375 INR 25733

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com